Slide1 ABL_0496Final

ABL is here to support your global production requirements

Slide2 shutterstock_1395953273
Where operational excellence meets regulatory rigor!


Global Leader In Biomanufacturing
Expanding To Meet Your Needs


Expanding Global Capacity

  • Increase biomanufacturing and immunology capacities  to support global clinical trials
  • Full complement of adherent cell production options (i.e. HYPERStacks®, cell factories and roller bottles)
  • Experience manufacturing products for gene therapies, vaccines oncolytic vectors, proteins and critical reagents
  • New iCELLis® GMP production suites
  • New facility in Lyon, France increases GMP production by greater than 50%

Newly Added iCELLis® Technology

  • ABL’s recently added iCELLis® 500+ fixed-bed bioreactor provides a significant increase in volumetric productivity verses classical adherent methods
  • iCELLis® capability in process development laboratory and GMP suites creates predictable scalability from R&D to manufacturing
  • New technology to meet your capacity requirements, streamline scalability and accelerate time to market

Global Commercial Ready

  • Commercial facilities in the U.S. and Europe (2021-22)
  • FDA and EMA compliant
  • Viral vector and protein products produced for:
    – Gene therapies
    – Vaccines
    – Oncolytics
    – Immunotherapies

See how our new capabilities can work for you. Our representatives are waiting to align our biomanufacturing offerings to your business strategy